Compare Abeona Therapeutics Inc (ABEO) vs Deckers Outdoor Corp (DECK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Deckers Outdoor Corp — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Deckers Outdoor Corp trades at $102.75 (market cap $14.73B). The key difference: Deckers Outdoor Corp is far larger — about 39.5× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Deckers Outdoor Corp nearer its low. Which is the better fit depends on your goals.
| ABEO | DECK | |
|---|---|---|
Market Cap | $373.32M | $14.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $123.91 |
52-Week Low | $4.17 | $79.54 |
Enterprise Value | $228.22M | $13.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Deckers Outdoor Corp (DECK) trades at $106.08, up 1.33% today, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.99B in 2025, with net income reaching $966M and a robust ROE of 40.86%. Recent quarters show consistent earnings beats, and analyst consensus targets $121.50. The stock benefits from international expansion of UGG and HOKA brands, as highlighted by Zacks Investment Research on 2026-07-01.
The outlook for DECK is positive, supported by earnings momentum and global growth initiatives, but risks include competitive pressures and market volatility. With a P/E of 15.05, the stock appears reasonably valued, offering potential upside to the consensus target. Investors should weigh strong profitability against sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →
